[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"eosinophilic-granulomatosis-with-polyangiitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:eosinophilic-granulomatosis-with-polyangiitis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,56,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":34,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100283245","vcrc-tissue-repository-100283245",false,"NCT02967068","VCRC Tissue Repository","VCRC Tissue Biorepository Collection Protocol","Inclusion Criteria:\n\n* A participant will be deemed eligible for this study if the participant is\u002Fwas enrolled in another one of the VCRC observational\u002Flongitudinal protocols (5502, 5503, 5504, 5505, 5506, 5507, 5563) and\u002For one of the VCRC interventional studies (5522, 5523, 5526, 5527, or 5562).\n\nExclusion Criteria:\n\n* Inability to give informed consent (or their guardians in the case of children) and to sign the consent form.\n* Unwilling to allow the use of their tissue for research.","ALL",{"count":18,"type":19},1000,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to collect existing tissue specimens from subjects enrolled in Vasculitis Clinical Research Consortium (VCRC) studies. Analysis of these tissue specimens and linked clinical data collected through VCRC studies may lead to the identification and development of a series of translational research projects. Results of these studies will provide vasculitis researchers with insight into the causes of these diseases and generate new ideas for diagnostic tests and therapies, and will be of great interest to the larger communities of researchers investigating vasculitis and other autoimmune, inflammatory, and vascular diseases.",[23,24,25,26,27,28,29,30,31,32,33],"Aortitis","Cutaneous Vasculitis","Eosinophilic Granulomatosis With Polyangiitis","Giant Cell Arteritis","Granulomatosis With Polyangiitis (Wegener's)","Henoch-Schonlein Purpura","IgA Vasculitis","Microscopic Polyangiitis","Polyarteritis Nodosa","Takayasu Arteritis","Churg-Strauss Syndrome",[35,36,37,38,39,40,41,42],"CSS","EGPA","GCA","GPA","MPA","PAN","TAK","HSP","RECRUITING","2026-01-21",{"date":46,"type":47},"2026-01-22","ACTUAL",{"date":49,"type":47},"2016-11",{"date":51,"type":19},"2028-12",{"name":53,"class":54},"University of Pennsylvania","OTHER",8,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":73,"locationsCount":74},"100081347","longitudinal-study-for-eosinophilic-granulomatosis-with-polyangiitis-100081347","NCT00315380","Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis","Longitudinal Protocol for Eosinophilic Granulomatosis With Polyangiitis","Inclusion Criteria:\n\nPatients with a diagnosis of eosinophilic granulomatosis with polyangiitis are eligible for the study.\n\nParent or guardian willing to provide informed consent, if applicable\n\nExclusion Criteria:\n\n\\- Inability to give informed consent and to sign the consent form",{"count":64,"type":19},700,"Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA.",[25,33],[36,35],{"date":69,"type":47},"2026-01-23",{"date":71,"type":4},"2006-04",{"date":51,"type":19},{"name":53,"class":54},13,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":86,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":97,"locationsCount":100},"100514480","phase-2-a-study-to-evaluate-the-efficacy-and-safety-of-shr-1703-in-subjects-with-eosinophilic-granulomatosis-with-polyangiitis-egpa-100514480","NCT05979051","A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）","A Multicenter, Single-arm\u002FRandomized, Double-blind, Active-controlled, Parallel-group Phase 2\u002F3 Clinical Study to Evaluate the Efficacy and Safety of SHR-1703 for Patients With EGPA","Inclusion Criteria:\n\n1. Male or female subjects age 18 years or older;\n2. Diagnosed with EGPA for at least 6 months;\n3. History of relapsing or refractory EGPA；\n4. Stable dose of oral prednisone of ≥7.5 mg\u002Fday (but not \\>50 mg\u002Fday) for at least 4 weeks prior to randomization;\n5. If receiving immunosuppressive therapy (excluding cyclophosphamide), the dosage must be stable within 4 weeks prior to randomization and during the study.\n\nExclusion Criteria:\n\n1. Subjects with other eosinophilic-related diseases;\n2. Diagnosed with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).\n3. Life-threatening EGPA within 3 months prior to randomization;\n4. Malignancy history within 5 years prior to randomization;\n5. Immunodeficiency;\n6. Uncontrolled hypertension；\n7. Uncontrolled cerebrovascular and cardiovascular disease;\n8. parasitic infection within 6 months prior to randomization;\n9. Active infectious disease requiring clinical treatment within 4 weeks prior to randomization;\n10. Subjects with a dose of oral prednisone of \\>50 mg\u002Fday within 4 weeks prior to randomization;\n11. Oral or intravenous cyclophosphamide therapy within 4 weeks prior to randomization;\n12. Intravenous or subcutaneous immunoglobulin within 12 weeks prior to randomization;\n13. Biological agents or TH2 cytokine inhibitors used within 12 weeks prior to randomization or within 5 half-lives of the drug;\n14. Rituximab used within 6 months prior to randomization；\n15. Surgical plans that might affect the evaluation;\n16. Significant laboratory abnormalities；\n17. Prolonged QTc interval or other electrocardiogram abnormalities with significant safety risk at screening;\n18. History of drug or substance abuse or alcohol abuse within 1 year prior to screening;\n19. Subjects participated another clinical study and received active drug within 30 days or 5 half-lives of the drug prior to screening;\n20. Subjects is pregnant, lactating, or planning to be pregnant;\n21. Subjects have a known history of hypersensitivity or intolerance to anti-IL-5 mabs or other biological agents or previous failure of IL-5\u002FIL-5R therapy;\n22. Other conditions unsuitable for participation in the study per investigator judgement.","18 Years",{"count":84,"type":19},166,"INTERVENTIONAL",[87,88],"PHASE2","PHASE3","This study is a phase 2\u002F3 clinical trial to evaluate the efficacy and safety of SHR-1703 in patients with EGPA.",[25],"2025-11-26",{"date":93,"type":47},"2025-12-04",{"date":95,"type":47},"2023-11-16",{"date":51,"type":19},{"name":98,"class":99},"Guangdong Hengrui Pharmaceutical Co., Ltd","INDUSTRY",2]